SCHEMBL15977835

SCHEMBL15977835

CC1(C)c2ccccc2-c2ccc(-c3c4ccccc4c(-c4ccc5c(c4)C(C)(C)c4ccccc4-5)c4cc(-c5ccc(-c6ccncc6)cn5)ccc34)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 5/20 0.40
MAPK10 P53779 1/20 0.35
PDPK1 O15530 1/20 0.33
PIK3CA P42336 3/20 0.33
NTRK1 P04629 1/20 0.32
IMPDH2 P12268 1/20 0.32
KIT P10721 1/20 0.32
ALOX5AP P20292 1/20 0.31
FEN1 P39748 1/20 0.31
HSD17B1 P14061 1/20 0.31
HSD17B2 P37059 1/20 0.31
PDGFRB P09619 1/20 0.31
PDGFRA P16234 1/20 0.31
CDC7 O00311 1/20 0.30
ROCK2 O75116 1/20 0.30
MAP4K4 O95819 1/20 0.30
PRKACA P17612 1/20 0.30
CDK2 P24941 1/20 0.30
GSK3B P49841 1/20 0.30
CLK4 Q9HAZ1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15977847 0.97 PDK2 (0.38) PDK2MAPK10PDPK1PIK3CAIMPDH2
SCHEMBL15977827 0.90 PDK2 (0.45) PDK2MAPK10PDPK1PIK3CAKIT
SCHEMBL15977559 0.90 PDK2 (0.49) PDK2PIK3CAIMPDH2CDC7ROCK2
SCHEMBL15977538 0.89 PDK2 (0.42) PDK2MAPK10PDPK1PIK3CANTRK1
SCHEMBL15977830 0.89 PDK2 (0.43) PDK2MAPK10PDPK1PIK3CAKIT
SCHEMBL15977523 0.88 PDK2 (0.46) PDK2
SCHEMBL13488126 0.87 PDK2 (0.46) PDK2PIK3CAIMPDH2HSD17B1HSD17B2
SCHEMBL15977514 0.87 PDK2 (0.47) PDK2MAPK10PIK3CAPDGFRBPDGFRA
SCHEMBL13487896 0.86 PDK2 (0.46) PDK2PIK3CAIMPDH2HSD17B1HSD17B2
SCHEMBL15977796 0.86 PDK2 (0.40) PDK2ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220416178-A1 COMPOSITION, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS IDEMITSU KOSAN CO.,LTD. (JP) 2022-12-29 US disclosed
US-9559311-B2 Anthracene derivative, organic-electroluminescence-device material, organic electroluminescence device, and electronic equipment IDEMITSU KOSAN CO., LTD. (JP) 2017-01-31 US disclosed
US-9559311-B2 Anthracene derivative, organic-electroluminescence-device material, organic electroluminescence device, and electronic equipment IDEMITSU KOSAN CO., LTD. (JP) 2017-01-31 US disclosed
US-20140239273-A1 ANTHRACENE DERIVATIVE, ORGANIC-ELECTROLUMINESCENCE-DEVICE MATERIAL, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC EQUIPMENT IDEMITSU KOSAN CO., LTD. (JP) 2014-08-28 US disclosed
US-20140239273-A1 ANTHRACENE DERIVATIVE, ORGANIC-ELECTROLUMINESCENCE-DEVICE MATERIAL, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC EQUIPMENT IDEMITSU KOSAN CO., LTD. (JP) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220416178-A1 COMPOSITION, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS PIEZO1, TMEM109, SLC39A14 PDK2 924/4885MAPK10 2313/4885PDPK1 2758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.